Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Mizoribine requires individual dosing due to variation of bioavailability.

Fuke T, Abe Y, Hibino S, Takeshi M, Saito T, Sakurai S, Watanabe S, Murayama J, Itabashi K, Nakano Y.

Pediatr Int. 2012 Dec;54(6):885-91. doi: 10.1111/j.1442-200X.2012.03733.x.

PMID:
23039376
2.

Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis.

Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E.

Clin Nephrol. 2005 Jun;63(6):417-22.

PMID:
15960142
3.

Mizoribine for the treatment of lupus nephritis in children and adolescents.

Tanaka H, Tsugawa K, Tsuruga K, Suzuki K, Nakahata T, Ito E, Waga S.

Clin Nephrol. 2004 Dec;62(6):412-7.

PMID:
15630899
4.

Population pharmacokinetics of mizoribine in pediatric patients with kidney disease.

Kaneda H, Shimizu M, Ohta K, Ushijima K, Gotoh Y, Satomura K, Nagai T, Fujieda M, Morooka M, Yamada T, Yamada M, Wada N, Takaai M, Hashimoto Y, Uemura O.

Clin Exp Nephrol. 2016 Oct;20(5):757-763. Epub 2015 Dec 9.

PMID:
26649561
5.

Pharmacokinetic study of mizoribine in child-onset glomerulonephritis.

Abe Y, Mikawa T, Fuke T, Hisano M, Tsuji Y, Watanabe S, Itabashi K.

Pediatr Int. 2008 Oct;50(5):615-9. doi: 10.1111/j.1442-200X.2008.02624.x.

PMID:
19261105
6.

Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the tohoku pediatric study group.

Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, Kondo Y, Suzuki J.

Nephron Clin Pract. 2008;110(2):c73-9. doi: 10.1159/000151721. Epub 2008 Sep 1.

PMID:
18758186
7.

Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.

Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E.

Pediatr Nephrol. 2006 Jul;21(7):962-6. Epub 2006 May 24.

PMID:
16773408
8.

A case of lupus nephritis improved after appropriately adjusting the dosage of mizoribine.

Tsubouchi Y, Fukuda W, Kawahito Y, Kohno M, Wada M, Ishino H, Hamaguchi M, Yamamoto A, Kadoya M, Niimi M, Yoshikawa T.

Mod Rheumatol. 2008;18(1):91-5. Epub 2007 Dec 26.

PMID:
18159569
9.

Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis.

Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S.

Clin Nephrol. 2003 Dec;60(6):390-4.

PMID:
14690255
10.

Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis.

Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T, Naito M, Koike M, Nitta K, Nihei H.

Clin Nephrol. 2005 Jul;64(1):28-34.

PMID:
16047642
11.

Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children.

Yoshidome K, Takei S, Imanaka H, Maeno N, Ohkawa T, Kawano Y.

Pediatr Int. 2004 Aug;46(4):444-9.

PMID:
15310311
12.

[Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome].

Goto M, Ikeda M, Hataya H, Ishikura K, Hamasaki Y, Honda M.

Nihon Jinzo Gakkai Shi. 2006;48(4):365-70. Japanese.

PMID:
16780106
13.

High-dose mizoribine treatment for adolescents with systemic lupus erythematosus.

Nozu K, Iijima K, Kamioka I, Fujita T, Yoshiya K, Tanaka R, Nakanishi K, Yoshikawa N, Matsuo M.

Pediatr Int. 2006 Apr;48(2):152-7.

PMID:
16635174
14.

Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy.

Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, Wada Y, Murakami S, Hasegawa H, Ito S, Sakatsume M, Nakano M, Gejyo F.

Mod Rheumatol. 2007;17(3):206-12. Epub 2007 Jun 20.

PMID:
17564775
15.

Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis.

Nishi E, Kameda H, Ogawa H, Nagasawa H, Takei H, Okuyama A, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Sakai R, Ito T, Takeuchi T, Amano K.

Mod Rheumatol. 2013 Jan;23(1):97-103. doi: 10.1007/s10165-012-0645-6. Epub 2012 Apr 22.

PMID:
22526831
16.
17.
18.

A case report of steroid-resistant antineutrophil cytoplasmic antibody-related vasculitis successfully treated by mizoribine in a hemodialysis patient.

Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Fujimatsu S, Muta T, Takeuchi M, Abe H, Okazaki M, Otsuji Y.

Ther Apher Dial. 2009 Feb;13(1):77-9. doi: 10.1111/j.1744-9987.2009.00601.x.

PMID:
19379174
19.

The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients.

Yoshimura N, Ushigome H, Akioka K, Nobori S, Suzuki T, Sakai K, Okamoto M.

Clin Exp Nephrol. 2013 Feb;17(1):127-33. doi: 10.1007/s10157-012-0669-4. Epub 2012 Aug 2.

PMID:
23011290
20.

Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis.

Ichinose K, Origuchi T, Kawashiri SY, Iwamoto N, Fujikawa K, Aramaki T, Kamachi M, Arima K, Tamai M, Nakamura H, Ida H, Kawakami A, Tsukada T, Ueki Y, Eguchi K.

Intern Med. 2010;49(20):2211-8. Epub 2010 Oct 15.

Supplemental Content

Support Center